Bacteria exhibit a myriad of different morphologies,
through the
synthesis and modification of their essential peptidoglycan (PG) cell
wall. Our discovery of a fluorescent D-amino acid (FDAA)-based PG labeling approach provided a powerful method
for observing how these morphological changes occur. Given that PG
is unique to bacterial cells and a common target for antibiotics,
understanding the precise mechanism(s) for incorporation of (F)DAA-based
probes is a crucial determinant in understanding the role of PG synthesis
in bacterial cell biology and could provide a valuable tool in the
development of new antimicrobials to treat drug-resistant antibacterial
infections. Here, we systematically investigate the mechanisms of
FDAA probe incorporation into PG using two model organisms Escherichia coli (Gram-negative) and Bacillus subtilis (Gram-positive). Our in vitro and in vivo data unequivocally demonstrate
that these bacteria incorporate FDAAs using two extracytoplasmic pathways:
through activity of their D,D-transpeptidases, and,
if present, by their L,D-transpeptidases and not
via cytoplasmic incorporation into a D-Ala-D-Ala
dipeptide precursor. Our data also revealed the unprecedented finding
that the DAA-drug, D-cycloserine, can be incorporated into
peptide stems by each of these transpeptidases, in addition to its
known inhibitory activity against D-alanine racemase and D-Ala-D-Ala ligase. These mechanistic findings enabled
development of a new, FDAA-based, in vitro labeling approach that
reports on subcellular distribution of muropeptides, an especially
important attribute to enable the study of bacteria with poorly defined
growth modes. An improved understanding of the incorporation mechanisms
utilized by DAA-based probes is essential when interpreting results
from high resolution experiments and highlights the antimicrobial
potential of synthetic DAAs.